[go: up one dir, main page]

BR0109164A - Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos - Google Patents

Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos

Info

Publication number
BR0109164A
BR0109164A BR0109164-6A BR0109164A BR0109164A BR 0109164 A BR0109164 A BR 0109164A BR 0109164 A BR0109164 A BR 0109164A BR 0109164 A BR0109164 A BR 0109164A
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
production
ldl receptor
human ldl
ldl
Prior art date
Application number
BR0109164-6A
Other languages
English (en)
Inventor
Nachum Yonah
Dany Suissa
Ilana Belzer
Antonetti Francesco
Smolarsky Moshe
Dreano Michel
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0109164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL13502500A external-priority patent/IL135025A0/xx
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0109164A publication Critical patent/BR0109164A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ANTICORPOS MONOCLONAIS PARA O RECEPTOR HUMANO PARA LDL, PRODUçãO E USO DOS MESMOS". São fornecidos anticorpos monoclonais para o receptor da LDL que são úteis para a identificação e para a purificação da LDL e no tratamento, por exemplo, da infecção pela hepatite C.
BR0109164-6A 2000-03-13 2001-03-08 Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos BR0109164A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13502500A IL135025A0 (en) 2000-03-13 2000-03-13 Monoclonal antibodies to the human ldl receptor, their production and use
IL13921700A IL139217A0 (en) 2000-03-13 2000-10-23 Monoclonal antibodies to the human ldl receptor, their production and use
PCT/IL2001/000216 WO2001068710A1 (en) 2000-03-13 2001-03-08 Monoclonal antibodies to the human ldl receptor, their production and use

Publications (1)

Publication Number Publication Date
BR0109164A true BR0109164A (pt) 2002-11-26

Family

ID=26323933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109164-6A BR0109164A (pt) 2000-03-13 2001-03-08 Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos

Country Status (33)

Country Link
US (1) US6849720B2 (pt)
EP (1) EP1263790B1 (pt)
JP (1) JP4768193B2 (pt)
KR (1) KR100882081B1 (pt)
CN (1) CN1418225B (pt)
AR (1) AR028518A1 (pt)
AT (1) ATE362490T1 (pt)
AU (2) AU4100201A (pt)
BG (1) BG65762B1 (pt)
BR (1) BR0109164A (pt)
CA (1) CA2402593C (pt)
CY (1) CY1108020T1 (pt)
CZ (1) CZ20023098A3 (pt)
DE (1) DE60128452T2 (pt)
DK (1) DK1263790T3 (pt)
EA (1) EA007494B1 (pt)
EE (1) EE200200517A (pt)
ES (1) ES2282238T3 (pt)
HK (1) HK1055750A1 (pt)
HR (1) HRP20020704B1 (pt)
HU (1) HU226194B1 (pt)
IL (2) IL139217A0 (pt)
MX (1) MXPA02009091A (pt)
NO (1) NO330904B1 (pt)
NZ (1) NZ520944A (pt)
PL (1) PL206041B1 (pt)
PT (1) PT1263790E (pt)
RS (1) RS51406B (pt)
SI (1) SI1263790T1 (pt)
SK (1) SK287348B6 (pt)
UA (1) UA78489C2 (pt)
WO (1) WO2001068710A1 (pt)
ZA (1) ZA200206654B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
CA2525517C (en) 2003-06-19 2016-05-31 Applied Research Systems Ars Holding N.V. Use of prion conversion modulating agents
FR2889532B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
EP1991869A2 (en) * 2006-02-17 2008-11-19 Paolo La Colla Methods for the diagnosis of proliferative and/or conformational diseases
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
IL188628A0 (en) * 2008-01-07 2008-12-29 Yeda Res & Dev Use of soluble ldl-r for viral hepatitis
GB0922377D0 (en) * 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
BR112012029881A2 (pt) 2010-05-25 2019-09-24 Inserm (Institut National De La Santé De La Recherche Médicale) combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
CN103111270B (zh) * 2013-02-26 2015-06-10 王业富 一种乙型肝炎抗原蛋白的吸附材料及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法

Also Published As

Publication number Publication date
HU226194B1 (hu) 2008-06-30
DE60128452T2 (de) 2007-09-13
DK1263790T3 (da) 2007-07-02
EA200200974A1 (ru) 2003-02-27
HUP0300142A3 (en) 2005-07-28
JP2004506603A (ja) 2004-03-04
UA78489C2 (en) 2007-04-10
NO20024223D0 (no) 2002-09-04
SI1263790T1 (sl) 2007-10-31
AU2001241002B2 (en) 2006-04-06
US6849720B2 (en) 2005-02-01
ZA200206654B (en) 2003-10-20
CN1418225A (zh) 2003-05-14
NZ520944A (en) 2004-04-30
MXPA02009091A (es) 2005-06-20
EP1263790B1 (en) 2007-05-16
CY1108020T1 (el) 2013-09-04
KR20020089384A (ko) 2002-11-29
EA007494B1 (ru) 2006-10-27
SK13122002A3 (sk) 2003-04-01
CN1418225B (zh) 2012-04-18
PT1263790E (pt) 2007-06-01
NO330904B1 (no) 2011-08-15
HRP20020704A2 (en) 2004-12-31
AR028518A1 (es) 2003-05-14
DE60128452D1 (de) 2007-06-28
HRP20020704B1 (en) 2011-01-31
PL206041B1 (pl) 2010-06-30
AU4100201A (en) 2001-09-24
WO2001068710A1 (en) 2001-09-20
JP4768193B2 (ja) 2011-09-07
CA2402593A1 (en) 2001-09-20
IL151713A0 (en) 2003-04-10
RS51406B (sr) 2011-02-28
EP1263790A1 (en) 2002-12-11
CZ20023098A3 (cs) 2003-02-12
EE200200517A (et) 2004-02-16
NO20024223L (no) 2002-10-24
AU2001241002B8 (en) 2006-05-04
KR100882081B1 (ko) 2009-02-10
HK1055750A1 (en) 2004-01-21
BG107063A (bg) 2003-05-30
IL139217A0 (en) 2001-11-25
PL358381A1 (en) 2004-08-09
SK287348B6 (sk) 2010-08-09
ES2282238T3 (es) 2007-10-16
BG65762B1 (bg) 2009-10-30
YU68602A (sh) 2006-03-03
US20030186343A1 (en) 2003-10-02
ATE362490T1 (de) 2007-06-15
CA2402593C (en) 2012-07-03
HUP0300142A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
DK1200418T3 (da) Nematodicide trifluorbutener
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
BR0208338A (pt) Derivados de piridina
NO2016007I1 (no) Susoktokog
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1108020T1 (el) Μονοκλωνικα αντισωματα στον ανθρωπινο υποδοχεα ldl, η παραγωγη και χρηση τους
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
EA199800946A1 (ru) Концентрированный препарат антител
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
SE9704546D0 (sv) Novel compounds
ID23374A (id) Halogenopirimidin
DE59610469D1 (de) Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparate
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DK0605753T3 (da) Cyclodextrin-inklusionskompleks af taxol, fremgangsmåde til fremstilling heraf og anvendelse heraf
BR9808923A (pt) Composto, e, processo para fazer o mesmo
BR0316400A (pt) agentes branqueadores fluorescentes anfotéricos
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
BRPI0416201A (pt) métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements